Ernexa Therapeutics Provides Update on Operational Excellence and Performance
Ernexa Therapeutics Inc. (ERNA)
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided an update on its operational excellence and performance for the first half of 2025. The company reported its financial results in its Quarterly Report on Form 10-Q for the period ending on June 30, 2025, filed with the Securities and Exchange Commission on August 13, 2025. The substantial year-over-year improvements were driven by focused execution and cost discipline as the company advances its lead cell therapy product, ERNA-101 for ovarian cancer, toward clinical studies, as well as further progressing ERNA-201 for autoimmune disease. Ernexa is a stronger company today due to the following operational milestones achieved during the first half of this year: Operating loss decreased by $5.5 million, or 51%, from $10.7 million during the six months ending on June 30, 2024 to $5.2 mi
Show less
Read more
Impact Snapshot
Event Time:
ERNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERNA alerts
High impacting Ernexa Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ERNA
News
- Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswire
- Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOGGlobeNewswire
- Ernexa Therapeutics to Present at Oxford Global's Cell 2025 [Yahoo! Finance]Yahoo! Finance
- Ernexa Therapeutics to Present at Oxford Global’s Cell 2025GlobeNewswire
- Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials [Yahoo! Finance]Yahoo! Finance